ArticleClinical drug investigation2020
Early and Late Switch from Ranibizumab to an Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema in the Event of a Poor Anatomical Response.
Article in Clinical drug investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Early Switch to Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema Poorly Responding to Anti-VEGF Therapy: A Narrative Review.Ophthalmology and therapy · 2026Review
- Comparison of Patients with Diabetic Macular Edema Undergoing Early versus Late Switch from Intravitreal Anti-VEGF Therapy to Dexamethasone Implant.Beyoglu eye journal · 2026Article
- What have we learned from a decade treating patients with diabetic macular oedema with 0.19 mg fluocinolone acetonide intravitreal implant?Eye (London, England) · 2025Review
- Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review.Life (Basel, Switzerland) · 2024Review
- Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion.International journal of ophthalmology · 2024Article
- Should intravitreal dexamethasone implant in refractory diabetic macular edema be used as an adjuvant therapy or switch therapy?Arquivos brasileiros de oftalmologia · 2024Article
- Dexamethasone implant in naive versus refractory patients with diabetic macular edema: a Meta-analysis.International journal of ophthalmology · 2024Article
- Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.BMJ open ophthalmology · 2023Observational
- Early-switch versus late-switch in patients with diabetic macular edema: a cost-effectiveness study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Diabetic Macular Oedema Guidelines: An Australian Perspective.Journal of ophthalmology · 2023Review
- Healthcare expenditure of intravitreal anti-vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema.Acta ophthalmologica · 2022Article
- Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update.Journal of clinical medicine · 2021Review
- Intravitreal Therapy for Diabetic Macular Edema: An Update.Journal of ophthalmology · 2021Review
- Intravitreal dexamethasone implant in naïve and previously treated patients with diabetic macular edema: a retrospective study.International journal of ophthalmology · 2020Article
- Can the dexamethasone intravitreal implant Ozurdex be safely administered in an out-of-operating room setting?Journal of drug assessment · 2020Article
- Quantitative Analysis of Retinal Microvascular Perfusion and Novel Biomarkers of the Treatment Response in Diabetic Macular Edema.Journal of diabetes research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePatients with diabetic macular edema may not have optimal outcomes even with monthly ranibizumab intravitreal injections. A corticosteroid implant might be considered in such patients. The objective of this study was to compare the outcomes of switching from ranibizumab to an intravitreal dexamethasone implant after three or six consecutive monthly injections of ranibizumab.
methodsPatients with treatment-naïve diabetic macular edema who showed a poor anatomical response to three or six consecutive intravitreal ranibizumab injections and received an intravitreal dexamethasone implant were enrolled in this retrospective study. Patients were divided into two groups as early- and late-switch groups. The early-switch group consisted of the patients who initially received three consecutive monthly ranibizumab injections and the late-switch group consisted of the patients who initially received six consecutive monthly ranibizumab injections and switched to a dexamethasone implant because of a poor anatomical response. Best corrected visual acuity and central retinal thickness at the baseline and 3, 6, 9, and 12 months in the study population were recorded.
resultsSixty-eight eyes of 68 patients were included. The early-switch group consisted of 34 eyes and the late-switch group consisted of 34 eyes. The mean change in best corrected visual acuity was similar between the two groups at 3, 9, and 12 months; however, it was significantly better in the early-switch group than the late-switch group at 6 months. The change in central retinal thickness was similar between the two groups at 3, 9, and 12 months; however, it was significantly better in the early-switch group than the late-switch group at 6 months.
conclusionsAlthough both early switching and late switching are similar in terms of providing functional and morphological improvement, early switching appeared better for ensuring patient well-being in the early period and improving patient adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.